Anti-A-beta Antibody Mutation for Yield and Stability

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for Alzheimer's disease, particularly those targeting amyloid-related disorders, have limited efficacy and are associated with adverse events, necessitating the development of more effective therapies that can arrest or delay disease progression.

Innovation Solution

Development of antibodies against the human A-beta protein with improved technical and biological properties, specifically by introducing a mutation in the heavy chain CDR2 and shortening the heavy chain CDR3, enhancing production properties, target binding, and plaque binding capabilities.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If conventional anti-A-beta antibodies are used for Alzheimer's treatment, then some therapeutic effect is achieved, but production yield is low and thermal stability is insufficient

Engineering Contradiction:

Improveproduction yieldVSAvoidthermal stability

Core Design Contradiction:

ProductivityVSReliability

Solution Approach 1:

The patent applies parameter changes by modifying specific amino acid residues in the antibody sequence (changing parameters at positions 234-235, 329, and 435) to simultaneously improve production yield and thermal stability. These sequence parameter modifications enable the antibody to achieve both higher productivity and enhanced reliability without compromise

Inventive Principle:

Principle #35Parameter changes

2Reliability

If existing anti-A-beta antibodies are used, then A-beta binding is achieved, but plaque binding capability is limited and efficacy is insufficient

Engineering Contradiction:

Improvetarget bindingVSAvoidplaque binding capability

Core Design Contradiction:

ReliabilityVSProductivity

Solution Approach 1:

The patent applies local quality by optimizing specific regions of the antibody structure - particularly the complementarity determining regions (CDRs) that contact A-beta and plaque proteins. By improving the local binding quality at these critical sites, the antibody achieves enhanced both target binding reliability and plaque binding capability simultaneously

Inventive Principle:

Principle #3Local quality

3Ease of operation

If current Alzheimer's treatments are used, then symptomatic benefit is achieved, but disease progression is not arrested or delayed

Engineering Contradiction:

Improvesymptomatic benefitVSAvoiddisease progression

Core Design Contradiction:

Ease of operationVSDuration of action of moving object

Solution Approach 1:

The patent converts the limited efficacy of conventional treatments into a benefit by designing antibodies that simultaneously provide symptomatic relief and disease-modifying effects. The antibody design transforms the previously harmful progression of the disease into a controllable process, extending the duration of beneficial action beyond mere symptom management

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Data Source

PatentUS20250051429A1Anti-a-beta protein antibodies, methods and uses thereof

Publication Date: 2025.02.13 F HOFFMANN LA ROCHE INC

AI summary

Herein is reported an antibody that binds to human A-beta protein, wherein the antibody comprises a heavy chain variable domain (VH) and a light chain variable domain comprising CDRs selected from (1) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 83; or (2) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 83; or (3) CDRs of SEQ ID NO: 85, 86, 87, 81, 82 and 91; or (4) CDRs of SEQ ID NO: 85, 89, 87, 81, 82 and 91.